risk factors for the development of auditory toxicity in patients receiving aminoglycosides were determined from the analysis of 135 patients enrolled in three prospective , randomized , double-blind clinical trials of gentamicin , tobramycin , and amikacin .
C0002556
aminoglycosides
C0040341
tobramycin